Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gakis, G; Morgan, TM; Daneshmand, S; Keegan, KA; Todenhöfer, T; Mischinger, J; Schubert, T; Zaid, HB; Hrbacek, J; Ali-El-Dein, B; Clayman, RH; Galland, S; Olugbade, K; Rink, M; Fritsche, HM; Burger, M; Chang, SS; Babjuk, M; Thalmann, GN; Stenzl, A; Efstathiou, JA.
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Ann Oncol. 2015; 26(8):1754-1759
Doi: 10.1093/annonc/mdv230
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mischinger Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for PUC in 10 referral centers between 1993 and 2012. Kaplan-Meier analysis with log-rank testing was used to investigate the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean: 32 months; interquartile range: 5-48). Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy (ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery (P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of neoadjuvant treatment was significantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS (P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005). In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without ACH. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - mortality
- Adenocarcinoma - therapy
- Aged -
- Albumin-Bound Paclitaxel - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Carboplatin - administration & dosage
- Carcinoma, Squamous Cell - mortality
- Carcinoma, Squamous Cell - therapy
- Carcinoma, Transitional Cell - mortality
- Carcinoma, Transitional Cell - therapy
- Chemoradiotherapy - methods
- Chemotherapy, Adjuvant - methods
- Cisplatin - administration & dosage
- Cystectomy -
- Deoxycytidine - administration & dosage
- Deoxycytidine - analogs & derivatives
- Disease-Free Survival -
- Female -
- Fluorouracil - administration & dosage
- Humans -
- Ifosfamide - administration & dosage
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Mitomycin - administration & dosage
- Neoadjuvant Therapy - methods
- Paclitaxel - administration & dosage
- Perioperative Care -
- Retrospective Studies -
- Urethra - surgery
- Urethral Neoplasms - mortality
- Urethral Neoplasms - therapy
- Urinary Diversion -
- Find related publications in this database (Keywords)
- primary urethral carcinoma
- adjuvant
- neoadjuvant
- chemotherapy
- chemoradiotherapy